A US-based KOL provides insights into treatment and diagnosis rates, prescribing habits, key marketed brands and late-phase therapies for ADHD. Particular attention is paid to pipeline therapies centanafadine, CTx-1301 and Sunosi.

This interview was conducted on 11th September, 2024.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.  

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900.

For our disclosures, please read the Biomedtracker Research Standards.